We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of Resistant Hodgkin's Disease with CCNU, Etoposide and Prednimustine (CEP).
- Authors
Szántó, J.; Fleischmann, T.; Eckhardt, S.
- Abstract
Starting in January 1984, 63 patients with resistant Hodgkin's disease received CEP as salvage -usually third-line - chemotherapy. Complete response (CR) was achieved in 3%, partial response (PR) in 51%. The median duration of remission (CR + PR) was greater than 15 months. Treatment was generally well tolerated. Our results confirm that CEP is an effective therapeutic regimen in resistant Hodgkin's disease. Copyright © 1991 S. Karger AG, Basel
- Publication
Oncology, 1991, Vol 48, Issue 6, p456
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000226980